Regeneron Pharmaceuticals (REGN) Beats Q4 Earnings Estimates by $1.75

Regeneron Pharmaceuticals (NASDAQ:REGN) reported quarterly earnings results on January 30, 2026 that exceeded analyst expectations.

The Healthcare company reported earnings per share of $11.44, beating the consensus estimate of $9.69 by $1.75 per share. Revenue came in at $3.9B, beating the estimate of $3.8B.

Regeneron Pharmaceuticals's stock moved following the earnings release. The stock currently trades at $752.41 with a market capitalization of $77.2B.